Engineering extracellular vesicles as novel treatment options: exploiting herpesviral immunity in CLL

by Kathrin Gärtner, Manja Luckner, Gerhard Wanner, Reinhard Zeidler
Published 2019-12-01

EBV-gp350 confers B-cell tropism to tailored exosomes and is a neo-antigen in normal and malignant B cells--a new option for the treatment of B-CLL.

by Romana Ruiss, Simon Jochum, Ralph Mocikat, Wolfgang Hammerschmidt, Reinhard Zeidler
Published 2011-01-01

The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination.

by Simon Jochum, Andreas Moosmann, Stephan Lang, Wolfgang Hammerschmidt, Reinhard Zeidler
Published 2012-01-01

Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells.

by Chiara Rancan, Leah Schirrmann, Corinna Hüls, Reinhard Zeidler, Andreas Moosmann
Published 2015-06-01

AHNAK and inflammatory markers predict poor survival in laryngeal carcinoma.

by Claudia A Dumitru, Agnes Bankfalvi, Xiang Gu, Reinhard Zeidler, Sven Brandau, Stephan Lang
Published 2013-01-01

Conditional immortalization of human B cells by CD40 ligation.

by Martina Wiesner, Caroline Zentz, Christine Mayr, Rainer Wimmer, Wolfgang Hammerschmidt, Reinhard Zeidler, Andreas Moosmann
Published 2008-01-01

CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease

by Constanze Slabik, Maja Kalbarczyk, Simon Danisch, Reinhard Zeidler, Frank Klawonn, Valery Volk, Nicole Krönke, Friedrich Feuerhake, Constanca Ferreira de Figueiredo, Rainer Blasczyk, Henning Olbrich, Sebastian J. Theobald, Andreas Schneider, Arnold Ganser, Constantin von Kaisenberg, Stefan Lienenklaus, Andre Bleich, Wolfgang Hammerschmidt, Renata Stripecke
Published 2020-09-01